Neumora Therapeutics (NMRA) Times Interest Earned (2025 - 2026)
Neumora Therapeutics' quarterly Times Interest Earned came in at -$28.51 in Q1 2026, up 0.73% quarter-over-quarter from -$28.72 in Q4 2025.
Neumora Therapeutics has reported Times Interest Earned for 2 years, with the latest figure at -$28.51 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned changed N/A year-over-year to -$28.51; the trailing twelve-month figure through Mar 2026 stood at -$48.11 (changed N/A YoY), and the FY2025 full-year result was -$74.92, changed N/A from the prior year.
- Times Interest Earned for Q1 2026 stood at -$28.51, up from -$28.72 in the prior quarter.
- The five-year high for Times Interest Earned was -$28.51 in Q1 2026, with the low at -$77.24 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -28.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.51 |
| Dec 31, 2025 | -28.72 |
| Sep 30, 2025 | -77.24 |